Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease

Kidney International

Volumn 88, Issue 4, 2015, Pages 833-842

  Sakaguchi, Yusuke ^a   Iwatani, Hirotsugu ^a   Hamano, Takayuki ^a   Tomida, Kodo ^b   Kawabata, Hiroaki ^a   Kusunoki, Yasuo ^a   Shimomura, Akihiro ^a   Matsui, Isao ^a   Hayashi, Terumasa ^b   Tsubakihara, Yoshiharu ^a   Isaka, Yoshitaka ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

chronic kidney disease; hyperphosphatemia; magnesium

Indexed keywords

CYTOKINE; MAGNESIUM; PHOSPHATE; BIOLOGICAL MARKER; MAGNESIUM SULFATE; SODIUM DIHYDROGEN PHOSPHATE;

ADULT; ANIMAL CELL; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEPOLARIZATION; DIET SUPPLEMENTATION; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HYPERPHOSPHATEMIA; IN VITRO STUDY; INCIDENCE; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; ANIMAL; APOPTOSIS; BLOOD; CELL LINE; CELL PROTECTION; COMPLICATION; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KAPLAN MEIER METHOD; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY PROXIMAL TUBULE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTECTION; RENAL INSUFFICIENCY, CHRONIC; TIME FACTOR;

ANIMALS; APOPTOSIS; BIOMARKERS; CELL LINE; CYTOKINES; CYTOPROTECTION; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; MAGNESIUM; MAGNESIUM SULFATE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; PHOSPHATES; PROTECTIVE FACTORS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS;

EID: 84942985772     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.165     Document Type: Article

References (41)

1. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 2011; 305: 1119-1127.
2. Schwarz S, Trivedi BK, Kalantar-Zadeh K et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 825-831.
3. Norris KC, Greene T, Kopple J et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006; 17: 2928-2936.
4. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916.
5. Chue CD, Edwards NC, Davis LJ et al. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol Dial Transplant 2011; 26: 2576-2582.
6. O'Seaghdha CM, Hwang SJ, Muntner P et al. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2011; 26: 2885-2890.
7. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930.
8. Bellasi A, Mandreoli M, Baldrati L et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 883-891.
9. Sim JJ, Bhandari SK, Smith N et al. Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med 2013; 126: 311-318.
10. Chartsrisak K, Vipattawat K, Assanatham M et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol 2013; 14: 14.
11. Mehrotra R, Peralta CA, Chen SC et al. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int 2013; 84: 989-997.
12. Ibels LS, Alfrey AC, Haut L et al. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978; 298: 122-126.
13. Neves KR, Graciolli FG, dos Reis LM et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244.
14. Cozzolino M, Dusso AS, Liapis H et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-2308.
15. Nagano N, Miyata S, Obana S et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003; 18: 2014-2023.
16. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010; 24: 3562-3571.
17. Qu X, Jin F, Hao Y et al. Magnesium and the risk of cardiovascular events: A meta-analysis of prospective cohort studies. PLoS One 2013; 8: e57720.
18. Larsson SC, Orsini N, Wolk A. Dietary magnesium intake and risk of stroke: A meta-analysis of prospective studies. Am J Clin Nutr 2012; 95: 362-366.
19. Del Gobbo LC, Imamura F, Wu JH et al. Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013; 98: 160-173.
20. Kanbay M, Yilmaz MI, Apetrii M et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012; 36: 228-237.
21. Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181.
22. Ishimura E, Okuno S, Kitatani K et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007; 68: 222-227.
23. Hruby A, O'Donnell CJ, Jacques PF et al. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imag 2014; 7: 59-69.
24. Kircelli F, Peter ME, Sevinc Ok E et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 2012; 27: 514-521.
25. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
26. Bernardi P. The mitochondrial permeability transition pore: A mystery solved? Front Physiol 2013; 4: 95.
27. Brenner C, Moulin M. Physiological roles of the permeability transition pore. Circ Res 2012; 111: 1237-1247.
28. Petit PX, Goubern M, Diolez P et al. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition. FEBS Lett 1998; 426: 111-116.
29. Gimenez LF, Solez K, Walker WG. Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney Int 1987; 31: 93-99.
30. Matsuzaki H, Katsumata S, Uehara M et al. Onset of nephrocalcinosis depends on dietary phosphorus concentration in male rats fed a magnesium-deficient diet. Magnes Res 2006; 19: 255-260.
31. Chiu YW, Adler S, Budoff M et al. Prevalence and prognostic significance of renal artery calcification in patients with diabetes and proteinuria. Clin J Am Soc Nephrol 2010; 5: 2093-2100.
32. Aihara K, Byer KJ, Khan SR. Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 2003; 64: 1283-1291.
33. Laquerriere P, Grandjean-Laquerriere A, Jallot E et al. Importance of hydroxyapatite particles characteristics on cytokines production by human monocytes in vitro. Biomaterials 2003; 24: 2739-2747.
34. Lutsey PL, Alonso A, Michos ED et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2014; 100: 756-764.
35. Sakaguchi Y, Shoji T, Hayashi T et al. Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease. Diabetes Care 2012; 35: 1591-1597.
36. Viñals F, Camps M, Testar X, Palacín M, Zorzano A. Effect of cations on the tyrosine kinase activity of the insulin receptor: inhibition by fluoride is magnesium dependent. Mol Cell Biochem 1997; 171: 69-73.
37. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial. Diabetes Care 2003; 26: 1147-1152.
38. Grafton G, Bunce CM, Sheppard MC, Brown G, Baxter MA. Effect of Mg2+ on Na(+)-dependent inositol transport. Role for Mg2+ in etiology of diabetic complications. Diabetes 1992; 41: 35-39.
39. Pham PC, Pham PM, Pham SV et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373.
40. Matsuo S, Imai E, Horio M et al. Collaborators developing the Japanese equation for estimated GFR Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
41. Namba T, Takabatake Y, Kimura T et al. Autophagic clearance of mitochondria in the kidney copes with metabolic acidosis. J Am Soc Nephrol 2014; 25: 2254-2266.